Background: HIV-1 drug resistance is an emerging challenge for HIV-1 infected clients who are on antiretroviral therapy (ART). In Kenya, as in many other developing countries, ART is now accessible to clients who need it. However, they must be done a CD4 test first and if the count is <300, then ART is commenced. With the initiation of ART comes the challenge of adherence to medication, a factor that is impacted greatly by the understanding of the client of the importance of adherence and the financial ability to keep their appointments, especially if the clients come from a distant location. Objective: To identify HIV-1 drug resistance mutations inclientsfailing1 st line antiretroviral therapy in Nairobi, Kenya. Methodology: A cross sectional study was carried out where whole blood samples were collected from clients attending a HIV care and treatment clinic in Nairobi. Clients who had been on ART for more than 6 months and had a viral load greater than 1000 were enrolled in the study. A total of 52 client samples were successfully sequenced in the reverse transcriptase region and analyzed. Results: After analysis of the generated sequences, it was seen that 43 (82.6%) of the clients had HIV-1 drug resistance mutations conferring resistance to one or more nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse-transcriptase inhibitors (NNRTIs). Majority of the clients (46%) were infected with HIV-1 subtype A viruses. Conclusion: The findings of the study showed that a significant proportion of the clients on ART had developed resistance mutations to one or more drugs that are used as 1 st line therapy in Kenya. There is need for continuous education of the population on importance of adherence to medication. There is also need for clinicians to be trained on using viral load and HIV drug resistance testing, where available, as methods of monitoring treatment failure so that clients can be * Corresponding author.
Introduction

Impact of HIV/AIDS
Global HIV/AIDS statistics show that as of 2012, there were 2.3 million new HIV-1 infections [1] . Sub-Saharan Africa accounts for more than 68% of the global prevalence of HIV, with women and the youth carrying the biggest burden of the disease [2] . Since the discovery of HIV-1 in Kenya in 1984, it continues to be a big healthcare burden for the country. The roll out of antiretroviral therapy (ART) has led to a significant reduction in HIV/AIDS related mortality [3] .
Use of ART in Management of HIV/AIDS
It is estimated that the cost of first line ART in some low and middle-income countries has been greatly reduced to around US $140 per person per year [1] . In 2013 the World Health Organization (WHO) revised the guidelines of ART initiation meaning that the number of eligible people for treatment initiation increased to approximately 28.6 million [4] . As of January 2011, there were 410,000 patients on ART in Kenya. The increase in ART coverage in the country is expected to lead to an increase in drug-resistant strains [5] . Stigma and cultural practices that affect ART uptake in Kenya may affect ART compliance, resulting in an increased emergence of drug-resistant mutants, which are a potential source of drug resistance. To mitigate against the development of HIV/AIDs drug resistance, the government of Kenya developed a guideline for clients who are due for initiationof ART. These include providing the clients with information on importance of ART and adherence to medication [6] .
Regimen Used for ART Management in Kenya
Initiation of ART in Kenya has been primarily based on CD4 count measurements [6] . It has also been shown that initiation of life-long triple therapy in pregnant mothers, regardless of their CD4 count is beneficial to the mother and drastically reduces the chances of transmission of the virus from the mother to the child [6] .
Currently the first-line treatment of HIV-1 and AIDS is based on the combination of two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI), which is also known as highly active antiretroviral therapy or HAART [7] . Most resource-limited countries use the standard first line regimens that were recommended by WHO [8] . In Kenya, initiation of ART in drug naïve clients is based on Tenefovir + Lamivudine + Efavirenz/Nevirapine [6] . In pregnant women where clients are unable to tolerate tenofovir then Zidovudine + Lamivudine + Efavirenz/Nevirapine have been used [6] .
Development of Resistance to ART
The most important enzyme in HIV multiplication in the body is reverse transcriptase (RT). The two main types of drugs used to inhibit RT are nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). NRTIs resemble nucleosides and are activated by the host to convert them to their triphosphate form. When bound in the active site, they terminate polymerization because they lack a 3' hydroxyl group [9] . NNRTIs are structurally different from the nucleoside RT inhibitors. They bind near the catalytic site of reverse transcriptase and alter the enzymes ability to change conformation. This increased enzyme rigidity prevents its normal polymerization function. Resistance to NNRTIs occurs when there are mutations in the binding pocket, and affinity for the drug is reduced.
According to the Kenya HIV-Drug resistant report of 2011 [10] , in order to establish treatment failure the following should be seen: New or recurrent WHO stage 4 condition or certain WHO clinical stage 3 conditions e.g. tuberculosis, plasma viral load above 1000 copies/ml and fall of CD4 count to baseline or persistent CD4 levels below 100 cells/mm 3 . Virological failure occurs earlier, which is later followed by immunological and clinical failure. Diagnostically, the reverse is true in resource-limited settings, because of availability diagnostic resources. Viral load is the most sensitive prognostic tool to identify treatment failure and is used in resourcerich settings [11] . Although resistance testing is not widely employed in developing countries due to the costs involved, the need will increase due to emergence of drug resistance as antiretroviral therapy is scaled up [12] .
Materials and Methods
Enrolment of Clients
This study was carried out to detect HIV-1 drug resistance mutations in ART-experienced clients who were seen to have virological and clinical failure. Blood samples were collected from clients aged 18 years and above and on 1 st line treatment for more than 6 months, with a CD4 count of below 350 cells/ml and/or patients with persistently high viral load in spite of being adherent to ART. Consenting was done before sample collection and testing. The study commenced after obtaining ethical clearance from the KEMRI/National ethical review committee. After getting informed consent from the clients, 3 ml of whole blood was collected. Plasma was separated and stored at -80˚C until when RNA was extracted from them.
Laboratory Methods
Viral RNA was extracted from the cryopreserved plasma samples using the Qiagen  RNA extraction kitas per the manufacturer's specifications. A single step RT and nested PCR was done using in-house primers targeting the protease and reverse transcriptase regions of the HIV-1 pol gene as previously described [11] . The reverse transcriptase gene was amplified and sequenced. The generated sequences were analyzed for subtype diversity using the REGA subtyping tool [13] and BLAST tool [14] . Drug resistance was determined using the International Aids Society (IAS) algorithm and the Stanford University HIV database.
Fifty-two samples were successfully sequenced and analyzed. The clients were aged 18 to 72 years with (Median age of 36years). Of the 52 subjects 36 were female and 16 male. The Median CD4 count of the subjects was 172 cell/ul (CD4 range 10 -350 cells/ul), with a mean of 178 cells/ul.The viral load of the clients ranged from 1234 to 2465798 copies (median: 58070 copies).
Results
After sequencing of the RT region and analysis of the same, it was determined that 43 (82%) of the clients had mutations conferring resistance to one or more NRTIs and NNRTIs. Analysis of the sequences showed that 36 (83.7%) of the clients with drug resistance mutations had NRTI drug mutations while 40 (93%) of the clients with drug resistance mutations had NNRTI related drug resistance mutations. Thirty three (76.7%) of these clients had both NRTI and NNRTI related drug resistance mutations ( Table 1) .
Discussion
The study showed that 82.6% of the clients enrolled in this study had HIV-1 drug resistance mutations conferring resistance to one or more NRTI and NNRTI drugs. This was high but was expected because these clients were failing clinically and virologically. These clients had an age range of 18 to 72 years with (Median age of 36 years). Many clients who access ART clinics feature in the age bracket of 15 -49 years, which is the age bracket hardest hit by the HIV epidemic [15] .
In sub-Saharan Africa, the common HIV-1 drug resistance profiles include the M184V mutation which is linked to resistance to nucleoside reverse transcriptase inhibitors, and the K103N mutation which is linked to resistance to non-nucleoside reverse transcriptase inhibitors; NNRTIs). The less common HIV-1 drug resistance mutations that have been seen in sub-Saharan Africa include Thymidine analogue mutations (TAMs) and the K65R mutation, which are less common [16] . In this study, this was also evident ( Table 1) , with a variety of other mutations being reported as well. , EFV  955046  28  M41L, M184V, T215F  3TC, AZT,  D4T, FTC   V106M,  Y188C,  G190A   EFV, NVP  A2   252  M  3TC, D4T, EFV  23456  290  NONE  NONE  K103N EFV, NVP  D   288  F  3TC, NVP, TDF  42345  280  M41L, K65N, M184V,  L210W, T215Y   3TC, ABC,  AZT, D4T,  DDI, FTC, TDF   Y188C,  H221Y  NVP  A1   307  M  3TC, NVP, TDF  3000  324  NONE  NONE  K103N EFV, NVP  D   322  M  3TC, AZT, EFV  45689  150   D67N, T69N, K70R,  M184V, T215F,  K219Q   3TC, ABC,  AZT, D4T,  DDI, FTC   K103N,  V108I,H22  1`Y   EFV, NVP  A1   384  F  3TC, AZT, EFV  1543  348  NONE  NONE  K103N EFV, NVP  D   412  M  3TC, D4T, NVP  675778  64  M41L, V75T  D4T   V90I,  V106M,  V179D   EFV, NVP  C   430  F  3TC, EFV, NVP  35467  125  M184V  3TC  NONE  NONE  B   433  F  3TC, AZT, EFV  1324  348  NONE  NONE  K103N EFV, NVP  D   439  M  3TC, EFV, TDF  255677  77  K65R  DDI, TDF   V90I,  K103N,  V108I EFV, NVP A1 466  F  3TC, D4T, NVP  893123  71 M41L, M184V, T215Y  3TC, AZT,  D4T, FTC  K103N EFV, NVP  C   516  M  3TC, D4T, NVP  230144  110 M41L, M184V, T215F  3TC, AZT,  D4T, FTC   V106M,  Y188C,  G190A   EFV, NVP  D   544  F  3TC, AZT, EFV  5128  290  M41L, L74I, M184V,  T215Y   3TC, ABC,  AZT, D4T,  DDI, Of the 52 subjects that were enrolled in the study, 36 were female and 16 were male. The Median CD4 count of the subjects was 172 cell/ul (CD4 range 10 -350 cells/ul), while the viral load ranged from 1234 to 2,465,798 copies (median: 58,070 copies). This showed that the clients were failing treatment and hence the high HIV-1 drug resistance rates were not unexpected. Additionally, most of the clients enrolled in the study were infected with HIV-1 subtype A viruses (46%). This was not unexpected as HIV-1 subtype A viruses are the common viruses circulating in Kenya [17] .
Continued
This study serves to show the importance of monitoring treatment failure using CD4 and viral load in resource limited settings as they serve as prognostic markers for detecting resistance. In addition, it shows that importance of use of HIV drug resistance testing in determining the specific drug resistance mutations and the equivalent drugs that the patients are failing. This is important in switching to more efficient therapies.
